This trial is testing a combination of two drugs to treat bladder cancer that has spread to other places in the body and has genetic alterations in FGFR2/3 genes. The first drug, erdafitinib, works by blocking the action of an abnormal FGFR protein that signals cancer cells to multiply. The second drug, enfortumab vedotin, is a monoclonal antibody that attaches to a protein called nectin-4 on cancer cells and delivers an anticancer drug to kill them. The combination of these two drugs may help to shrink or stabilize the cancer.
3 Primary · 4 Secondary · Reporting Duration: Up to 2 years
30 Total Participants · 1 Treatment Group
Primary Treatment: Erdafitinib · No Placebo Group · Phase 1
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: